PHAM
GPCR icon

Pacific Heights Asset Management’s Structure Therapeutics GPCR Stock Holding History

Pacific Heights Asset Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.9M Buy
800,000
+50,000
+7% +$2.21M 1.36% 17
2026
Q1 		$36.1M Buy
750,000
+50,000
+7% +$3.42M 1.21% 18
2025
Q4 		$48.7M Hold
700,000
– – 1.82% 10
2025
Q3 		$19.6M Buy
700,000
+240,000
+52% +$4.78M 0.87% 37
2025
Q2 		$9.54M Buy
+460,000
New +$10.1M 0.51% 62

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Pacific Heights Asset Management's GPCR Position: Q2 2026 in Review

Pacific Heights Asset Management increased its Structure Therapeutics (GPCR) stake by 6.7% in Q2 2026, buying an estimated $2.21M and bringing the position to 800,000 shares worth $42.9M. The position accounts for 1.36% of the portfolio, ranked #17.

Pacific Heights Asset Management first reported a position in GPCR in Q2 2025 and has held it in 5 quarters since. The position peaked at $48.7M in Q4 2025. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Pacific Heights Asset Management held 800,000 shares of Structure Therapeutics worth $42.9M as of Q2 2026.
  • Pacific Heights Asset Management bought 50,000 Structure Therapeutics shares in Q2 2026, an estimated $2.21M.
  • Structure Therapeutics made up 1.36% of Pacific Heights Asset Management's portfolio in Q2 2026, its #17 holding.
  • Pacific Heights Asset Management first reported a position in Structure Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Pacific Heights Asset Management's Structure Therapeutics position peaked at $48.7M in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Pacific Heights Asset Management's 13F filing for Q2 2026, filed 17 Aug 2026.